The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NOTV | -55.89% | -78.98% | -26.78% | -86% |
| S&P | +12.65% | +91.73% | +13.89% | +608% |
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
No news articles found for Inotiv.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $130.68M | 23.5% |
| Gross Profit | $19.94M | 186.4% |
| Gross Margin | 15.26% | 8.7% |
| Market Cap | $62.52M | 45.0% |
| Market Cap / Employee | $0.03M | 0.0% |
| Employees | 2.1K | 0.0% |
| Net Income | -$17.58M | 32.6% |
| EBITDA | $9.05M | 1021.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.22M | -56.9% |
| Accounts Receivable | $79.97M | 22.8% |
| Inventory | 64.3 | 9.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $432.74M | 987.4% |
| Short Term Debt | $15.48M | -96.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.29% | 1.9% |
| Return On Invested Capital | -18.50% | -3.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.45M | 40.4% |
| Operating Free Cash Flow | -$7.45M | 49.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.24 | 0.63 | 0.44 | 0.40 | 90.94% |
| Price to Sales | 0.09 | 0.24 | 0.16 | 0.12 | 43.69% |
| Price to Tangible Book Value | -0.23 | -0.54 | -0.39 | -0.32 | 34.27% |
| Price to Free Cash Flow TTM | 23.39 | 29.52 | - | ||
| Enterprise Value to EBITDA | 147.51 | -956.89 | 103.49 | 55.77 | -111.95% |
| Free Cash Flow Yield | 4.3% | 3.4% | - | ||
| Return on Equity | -49.3% | -56.9% | -48.0% | -48.5% | 11.89% |
| Total Debt | $445.12M | $447.11M | $451.59M | $448.21M | 4.29% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
